No profile data available.
CERo Therapeutics Holdings, Inc. (CERO) is a healthcare company in the blood cancer treatment drugs industry, based in South San Francisco, United States, with about 8 full-time employees.
In Q2 2025 (the quarter ended June 30, 2025) revenue was $0. Its market capitalization was $644,678 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
$644,678 as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include IN8bio, Inc. (INAB), Aptevo Therapeutics Inc. (APVO), Alaunos Therapeutics, Inc. (TCRT), Vincerx Pharma, Inc. (VINC).